Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07210723 · ClinicalTrials.gov registry record · Phase 2
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
A Phase 2 study of Symptomatic Genetic Dilated Cardiomyopathy, sponsored by Kardigan.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 332
- Enrollment target
- 18
- Study locations
NCT07210723: Recruiting Phase 2 study of Symptomatic Genetic Dilated Cardiomyopathy, sponsored by Kardigan.
NCT07210723 is a Phase 2 study of Symptomatic Genetic Dilated Cardiomyopathy that is actively recruiting participants, run by Kardigan. The registered enrollment target is 332 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (150% higher). The trial reports 18 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07210723, a Phase 2 study of Symptomatic Genetic Dilated Cardiomyopathy, is actively recruiting participants, sponsored by Kardigan.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 332 participants
- Enrollment target
- 18
- Study locations
Study Summary
The Sponsor is studying an investigational medication called danicamtiv to determine if it can help people with genetic and familial dilated cardiomyopathy (DCM). Investigational means that the safety and effectiveness of danicamtiv have not been established. Currently, there are no approved drugs that are designed specifically to treat genetic or familial DCM. The purpose of this study is to evaluate how well danicamtiv works compared to a placebo (sugar pill that looks like danicamtiv pill but does not contain any danicamtiv) and see how safe it is for people with genetic and familial DCM. In DCM, the heart muscle weakens and enlarges, making it harder for the heart to pump blood; this can happen for different reasons. Some people have DCM because of a change in a gene (called genetic DCM). Others may have DCM that runs in their family, even if no specific gene change is found (called familial DCM). The main goals of the study are: * To assess the effect of danicamtiv on cardiac function using echocardiogram. * To evaluate the impact of danicamtiv on exercise capacity * To evaluate the safety and tolerability of danicamtiv Participants will: * Take danicamtiv or placebo every day for approximately 6 months * Visit the clinic about 12 times for initial evaluation, checkups, tests and follow up
Conditions Studied
Interventions
- DRUG Placebo
- DRUG danicamtiv
Study Locations (18)
Other
- Hospital Universitario de A Coruña - A Coruña
- Hospital Clinico Universitario Virgen de la Arrixaca - Murcia
- Hospital Universitario Virgen del Rocio - Seville
- NHS Greater Glasgow and Clyde - Glasgow
- Royal Brompton Hospital - London
- Hammersmith Hospital, Imperial College of London - London
California
- Cedars Sinai - Los Angeles
- UCSF - San Francisco
Alabama
- University of Alabama Birmingham - Birmingham
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
Massachusetts
- Brigham and Women's Hospital - Boston
Michigan
- Henry Ford Health System - Detroit
Minnesota
- Mayo Clinic Rochester - Rochester
Missouri
- Washington University in St. Louis - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 332 participants |
| Start Date | 2026-02-13 |
| Est. Completion | 2028-01 |
| Phase | Phase 2 |
What NCT07210723 shows while recruiting
NCT07210723 is an interventional study that assigns participants to a tested intervention. The registered 332 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (150% higher).
The record links to 1 condition, with Symptomatic Genetic Dilated Cardiomyopathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07210723 lists 18 locations in 12 states (Other, California, Alabama).
Frequently Asked Questions
What is clinical trial NCT07210723 about?
NCT07210723 is a clinical study titled "A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy". The Sponsor is studying an investigational medication called danicamtiv to determine if it can help people with genetic and familial dilated cardiomyopathy (DCM). Investigational means that the safety and effectiveness of danicamtiv have not been established. Currently, there are no approved drugs t...
What is the current status of trial NCT07210723?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 332 participants. The study started on 2026-02-13. Estimated completion is 2028-01.
What conditions does trial NCT07210723 study?
This clinical trial studies the following conditions: Symptomatic Genetic Dilated Cardiomyopathy.
What interventions are being tested in trial NCT07210723?
The interventions under investigation include: Placebo (DRUG), danicamtiv (DRUG).
Who is sponsoring clinical trial NCT07210723?
This trial is sponsored by Kardigan, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07210723 being conducted?
This trial has 18 study locations across Alabama, California, District of Columbia, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07210723's enrollment target sits among peer trials
332 144th of 2000 higher than 1,856 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174121 · 332 participants · Phase 2
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- NCT02605785 · 332 participants · NA
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
- NCT04894006 · 332 participants · NA
Dementia Family Caregiver Study
- NCT05130606 · 332 participants · NA
CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI